Published • loading... • Updated
Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
Summary by Rockdale Citizen & Newton Citizen
18 Articles
18 Articles
The Paintsville Herald+17 Reposted by 17 other sources
Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
Presented interim FRONTIER4 data evaluate the long-term safety and efficacy of investigational denecimig across once-weekly, once-every-two-weeks, and once-monthly dosing in hemophilia A participants of all ages and disease severities1,2Denecimig is an investigational subcutaneous FVIIIa-mimetic antibody under review with the US…
Coverage Details
Total News Sources18
Leaning Left0Leaning Right3Center14Last UpdatedBias Distribution82% Center
Bias Distribution
- 82% of the sources are Center
82% Center
C 82%
R 18%
Factuality
To view factuality data please Upgrade to Premium
